Targeting cadherin-17 inactivates Ras/Raf/MEK/ERK signaling and inhibits cell proliferation in gastric cancer.
Cadherin-17 (CDH17), one member of 7D-cadherin superfamily, was overexpressed in gastric cancer (GC) and was associated with poor survival, tumor recurrence, metastasis, and advanced tumor stage. So far the cellular function and signaling mechanism of CDH17 in GC remains unclear. In this study, we showed that over 66% of GC cell lines (20/30) were CDH17 positive. Tissue microarray (TMA) assay showed that 73.6% Chinese GC tissues (159/216) were CDH17 positive, while 37% respective adjacent normal tissues were CDH17 positive. Knockdown of CDH17 inhibited cell proliferation, migration, adhesion and colony formation, and also induced a cell cycle arrest and apoptosis in AGS human GC cells. On the other side, overexpression of CDH17 facilitated MGC-803 GC tumor growth in nude mice. Antibody array and Western blotting assay demonstrated that knockdown of CDH17 in AGS cells down-regulated integrin β series proteins, further inactivated the Ras/Raf/MEK/ERK pathway and led to p53 and p21 accumulation, which resulted in proliferation inhibition, cell-cycle arrest and apoptosis induction. Collectively, our data firstly demonstrate the capacity of CDH17 to regulate the activity of Ras/Raf/MEK/ERK pathway for cell proliferation in GC, and suggest that CDH17 can serve as an attractive therapeutic target for future research.
Department of Discovery Technology, Roche Pharma Research and Early Development China, Shanghai, China.
Zhaohu
Z
Lin
Department of Discovery Technology, Roche Pharma Research and Early Development China, Shanghai, China.
Chao
C
Zhang
Department of Discovery Technology, Roche Pharma Research and Early Development China, Shanghai, China.
Meifang
M
Zhang
Department of Discovery Technology, Roche Pharma Research and Early Development China, Shanghai, China.
Danqing
D
Xu
Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, East China Normal University, Shanghai, China.
Yanfen
Y
Fang
Department of Discovery Technology, Roche Pharma Research and Early Development China, Shanghai, China.
Zheng
Z
Zhou
Department of Discovery Technology, Roche Pharma Research and Early Development China, Shanghai, China.
Xiaolong
X
Chen
Department of Discovery Technology, Roche Pharma Research and Early Development China, Shanghai, China.
Ning
N
Qin
Department of Discovery Technology, Roche Pharma Research and Early Development China, Shanghai, China ; Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, East China Normal University, Shanghai, China.
Xiongwen
X
Zhang
D000328:Adult; D000368:Aged; D000818:Animals; D015820:Cadherins / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000235:genetics / Q000502:physiology; D048049:Extracellular Signal-Regulated MAP Kinases / Q000235:genetics / Q000378:metabolism*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics / Q000378:metabolism*; D034741:RNA, Small Interfering; D015398:Signal Transduction / Q000235:genetics / Q000502:physiology; D013274:Stomach Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D046888:Tissue Array Analysis; D048490:raf Kinases / Q000235:genetics / Q000378:metabolism*
C490584:CDH17 protein, human; D015820:Cadherins; D034741:RNA, Small Interfering; D048490:raf Kinases; D048049:Extracellular Signal-Regulated MAP Kinases; D016283:Proto-Oncogene Proteins p21(ras)